Pleural disease

The Inner Circle Acknowledges, Rocco Terrigno, MD as a Pinnacle Lifetime Member

Retrieved on: 
금요일, 12월 29, 2023
Rowan University, Family, Inner circle, Learning, Sleep, Pneumonia, Critical Care Medicine (journal), Internal medicine, Critical care, Medical degree, Health, MD, Education, Football, Respiratory failure, Asthma, Pleural disease, Cooper University Hospital, COVID-19, Assistant, Growth, Publication, Patient, Diagnosis, Memory, Nursing care plan, Cough, Pulmonology

MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.

Key Points: 
  • MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.
  • Dr. Rocco Terrigno a renowned pulmonologist and critical care intensivist, is making a significant impact in the field of respiratory medicine.
  • Dr. Terrigno's expertise encompasses a wide range of respiratory conditions, including cough, interstitial lung disease/sarcoid, COPD/emphysema, asthma, sleep disorders, lung nodules, pleural disease, respiratory failure, and COVID-19 pneumonia.
  • Currently, Dr. Terrigno serves as a fellowship-trained pulmonologist and critical care intensivist in the Department of Critical Care Medicine at Cooper University Hospital in Camden, New Jersey.

BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis

Retrieved on: 
목요일, 10월 12, 2023
Diagnosis, Health, Highland, Pleural disease, Cancer, Disease, Lung cancer, Collaboration, Malignancy, Pleural cavity, Innovation, DNA, University, Neoplasm, NHS Highland, Immunology, Public, NHS, University of the Highlands and Islands, Lung, Infection, Nucleic acid thermodynamics, UHI, Patient, Medical imaging, Genetics

Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.

Key Points: 
  • Edinburgh, UK – 12 October 2023 – BIOCAPTIVA Ltd (“BIOCAPTIVA”), a company developing the BioCaptis – a revolutionary cell-free DNA (cfDNA) capture device designed to transform liquid biopsy testing for cancer management – announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.
  • The study will involve a collaboration between BioCaptiva, University of the Highlands and Islands (UHI) and NHS Highland.
  • The occurrence of cfDNA in exudative pleural fluid samples is well established, but it is often present in insufficient concentrations for sequencing to confirm a cancer diagnosis (versus benign disease).
  • This route to diagnosis is particularly challenging for frail elderly patients and therefore improving the diagnostic utility of pleural fluid has both clinical and health economic benefits.

Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting

Retrieved on: 
월요일, 10월 2, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Abstract, Cleveland Clinic, Lung transplantation, Liquid biopsy, Lung, Pleural disease, Patient, Annual general meeting, American College of Chest Physicians, Sightline (architecture), Pleural cavity, American College, Medical imaging, Lung cancer

The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.

Key Points: 
  • The presentation will showcase initial performance data from the Sightline study , a prospective multi-center, case-control study evaluating the performance of Lung EpiCheck, a non-invasive test to aid in the detection of early-stage lung cancer in high-risk patients.
  • Lung EpiCheck is being developed using markers discovered in Nucleix’s proprietary EpiCheck® Lung Atlas.
  • The Lung Atlas is an early lung cancer detection discovery platform that was constructed and developed as part of a multi-institutional effort to map epigenetic and genetic changes associated with early-stage lung cancer, focusing on stage I disease.
  • Session Title: Late-Breaking Development in Lung Cancer, Lung Transplantation, and Pleural Disease
    The CHEST 2023 abstracts will be available on the journal CHEST website at: https://journal.chestnet.org/meetings .

Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

Retrieved on: 
수요일, 10월 16, 2019
Other Health, Research, Radiology, Pharmaceutical, Oncology, Medical devices, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Cancer, RTT, Clinical medicine, Neoplasms, Mesothelioma, Pleural disease, Intrathoracic hyperthermic perfused chemotherapy, Other Health, Research, Radiology, Pharmaceutical, Oncology, Medical devices, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Cancer, RTT, Clinical medicine, Neoplasms, Mesothelioma, Pleural disease, Intrathoracic hyperthermic perfused chemotherapy, Malignant Pleural Mesothelioma (MPM), STELLAR, the NovoTTF-100L™ System, Novocure

Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology.
  • Malignant pleural mesothelioma is a rare thoracic solid tumor cancer that has been strongly linked to asbestos exposure.
  • The trial was designed for patients to receive Tumor Treating Fields at 150 kHz at least 18 hours a day until disease progression.
  • Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer

Retrieved on: 
화요일, 9월 25, 2018
Cancer, RTT, Respiratory system, Pleura, Asbestos, Mesothelioma, Pemetrexed, Pleural cavity, Lung cancer, Pulmonary pleurae, Asbestos-related diseases, Pleural disease

ADX-1612, when combined with standard pemetrexed and platinum therapy, resulted in partial response rates that exceeded historical standard of care.

Key Points: 
  • ADX-1612, when combined with standard pemetrexed and platinum therapy, resulted in partial response rates that exceeded historical standard of care.
  • Results will be announced at a presentation at the International Association for the Study of Lung Cancer (ASLC) 19th World Conference on Lung Cancer (Abstract #11921) on September 25, 2018.
  • Malignant pleural mesothelioma is a rare, aggressive cancer that develops in the pleura, a thin layer of tissue surrounding the lungs.
  • The company is also developing other product candidates for autoimmune disease, post-transplant lymphoproliferative disease, retinal inflammation, metabolic disease, and cancer.